Abstract: The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof. The present invention also provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.

Abstract: A digital audio workstation organizes musical information in a visually consistent manner, such that it is easier for the user to see and to manipulate the content in a song. The organization includes a multitrack music stream, which depicts multiple adjacent streams (or “tracks”) of musical content playing in parallel; a Play Bar, which is a visual plane intersecting the music stream; and two or more data layers, which are spatially aligned with the underlying musical stream, but each of which contains a specific type of musical data which can be viewed and manipulated in isolation. This approach to visual organization of music information has some major benefits to the user. Many different kinds of musical content and transformations can be depicted in a clear and consistent manner, making it easier for the user to see and manipulate the song.

Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-released solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention related to a methods of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowl disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following formula I: wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.

Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-released solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention related to a methods of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowl disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention relates to a method of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowel disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

Abstract: Novel methods to prepare novel polymers are disclosed. Oxazolidinyl compounds according to formula IV: are also disclosed as intermediate compounds that can be reacted with an acid to form a polymer of formula I.

Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following formula I: wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.

Abstract: An exemplary method includes performing a capture threshold assessment using a bipolar electrode configuration, deciding if capture occurred for a maximum energy value of the capture threshold assessment and, if capture did not occur, then performing a lead impedance test for the lead associated with the bipolar electrode configuration. Such a test may aim to detect an insulation defect and/or a conductor defect. Other exemplary methods, devices, systems, etc., are also disclosed.

Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.

Abstract: An exemplary method includes performing a capture threshold assessment using a bipolar electrode configuration, deciding if capture occurred for a maximum energy value of the capture threshold assessment and, if capture did not occur, then performing a lead impedance test for the lead associated with the bipolar electrode configuration. Such a test may aim to detect an insulation defect and/or a conductor defect. Other exemplary methods, devices, systems, etc., are also disclosed.

Abstract: Novel methods to prepare novel polymers are disclosed. Oxazolidinyl compounds according to formula IV: are also disclosed as intermediate compounds that can be reacted with an acid to form a polymer of formula I.

Abstract: An exemplary method includes performing a capture threshold assessment using a bipolar electrode configuration, deciding if capture occurred for a maximum energy value of the capture threshold assessment and, if capture did not occur, then performing a lead impedance test for the lead associated with the bipolar electrode configuration. Such a test may aim to detect an insulation defect and/or a conductor defect. Other exemplary methods, devices, systems, etc., are also disclosed.

Abstract: An exemplary method includes performing a capture threshold assessment using a bipolar electrode configuration, deciding if capture occurred for a maximum energy value of the capture threshold assessment and, if capture did not occur, then performing a lead impedance test for the lead associated with the bipolar electrode configuration. Such a test may aim to detect an insulation defect and/or a conductor defect. Other exemplary methods, devices, systems, etc., are also disclosed.

Abstract: An exemplary method includes performing a capture threshold assessment using a bipolar electrode configuration, deciding if capture occurred for a maximum energy value of the capture threshold assessment and, if capture did not occur, then performing a lead impedance test for the lead associated with the bipolar electrode configuration. Such a test may aim to detect an insulation defect and/or a conductor defect. Other exemplary methods, devices, systems, etc., are also disclosed.

Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention relates to a method of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowel disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.

Abstract: An implantable medical device is provided for detecting transportless ventricular rhythm of a heart lacking atrial transport and comprises a housing, sensors configured to be located proximate to a heart, a sensing module to sense cardiac signals representative of a rhythm originating from the heart and a rhythm detection module. The rhythm detection module determines a change in AV association and identifies a potential ventricular complex with loss of atrial transport (VCLAT) based on the change in AV association.

Abstract: An implantable medical device is provided for detecting transportless ventricular rhythm of a heart lacking atrial transport and comprises a housing, sensors configured to be located proximate to a heart, a sensing module to sense cardiac signals representative of a rhythm originating from the heart and a rhythm detection module. The rhythm detection module determines a change in AV association and identifies a potential ventricular complex with loss of atrial transport (VCLAT) based on the change in AV association.

Abstract: An implantable medical device is provided for detecting transportless ventricular rhythm of a heart lacking atrial transport and comprises a housing, sensors configured to be located proximate to a heart, a sensing module to sense cardiac signals representative of a rhythm originating from the heart and a rhythm detection module. The rhythm detection module determines a change in AV association and identifies a potential ventricular complex with loss of atrial transport (VCLAT) based on the change in AV association.